Stocks · News reference
Progyny shares are trading lower after the company reported Q2 financial results and lowered its FY26 sales guidance with its midpoint below estimates. Also, the company issued Q3GAAP EPS and sales guidance below estimates.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Concentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?
Concentra Group (CON) has reached a new 52-week high of $36.05, gaining 82% year-to-date and outperforming its sector. The company maintains a Zacks Rank #1 (Strong Buy) with consistent earnings beat records and a VGM Score of B. However, valuation metrics show the stock trades at a premium to peers (21.7X forward P/E vs. 17X industry average), raising questions about further upside potential.
Citizens Maintains Market Outperform on Progyny, Raises Price Target to $33
JP Morgan Maintains Neutral on Progyny, Raises Price Target to $30
JP Morgan analyst Lisa Gill maintains Progyny (NASDAQ:PGNY) with a Neutral and raises the price target from $27 to $30.